JP6647287B2 - 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド - Google Patents
多発性骨髄腫の治療に使用するためのキノリンカルボキサミド Download PDFInfo
- Publication number
- JP6647287B2 JP6647287B2 JP2017513751A JP2017513751A JP6647287B2 JP 6647287 B2 JP6647287 B2 JP 6647287B2 JP 2017513751 A JP2017513751 A JP 2017513751A JP 2017513751 A JP2017513751 A JP 2017513751A JP 6647287 B2 JP6647287 B2 JP 6647287B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- chloro
- fluoro
- compound
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185892.8 | 2014-09-23 | ||
| EP14185892 | 2014-09-23 | ||
| PCT/EP2015/071391 WO2016042112A1 (en) | 2014-09-23 | 2015-09-18 | Quinoline carboxamides for use in the treatment of multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528473A JP2017528473A (ja) | 2017-09-28 |
| JP2017528473A5 JP2017528473A5 (en:Method) | 2018-10-11 |
| JP6647287B2 true JP6647287B2 (ja) | 2020-02-14 |
Family
ID=51660309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513751A Active JP6647287B2 (ja) | 2014-09-23 | 2015-09-18 | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956212B2 (en:Method) |
| EP (1) | EP3041472B1 (en:Method) |
| JP (1) | JP6647287B2 (en:Method) |
| KR (1) | KR102533033B1 (en:Method) |
| CN (1) | CN107108510B (en:Method) |
| AU (1) | AU2015316824B2 (en:Method) |
| CA (1) | CA2961978C (en:Method) |
| EA (1) | EA030948B1 (en:Method) |
| ES (1) | ES2631194T3 (en:Method) |
| IL (1) | IL251043B (en:Method) |
| MX (1) | MX366837B (en:Method) |
| NZ (1) | NZ730816A (en:Method) |
| PL (1) | PL3041472T3 (en:Method) |
| WO (1) | WO2016042112A1 (en:Method) |
| ZA (1) | ZA201702377B (en:Method) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108510B (zh) * | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
| KR20220149579A (ko) * | 2020-03-03 | 2022-11-08 | 액티브 바이오테크 에이비 | 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염 |
| PL4185292T3 (pl) | 2020-07-23 | 2025-10-13 | Erasmus University Medical Center Rotterdam | Białka s100 jako nowe cele terapeutyczne w przypadku nowotworów mieloproliferacyjnych |
| MX2023008016A (es) | 2021-01-18 | 2023-07-13 | Active Biotech Ab | Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico. |
| PL4346773T3 (pl) | 2021-05-25 | 2025-11-03 | Active Biotech Ab | Duża liczba cząstek taskwinimodu i ich zastosowanie |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US9469876B2 (en) * | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| EA021171B1 (ru) | 2010-07-09 | 2015-04-30 | Эктив Байотек Аб | Способ получения хинолин-3-карбоксамидов |
| US20140148350A1 (en) * | 2010-08-18 | 2014-05-29 | David Spetzler | Circulating biomarkers for disease |
| WO2012034543A1 (es) | 2010-09-13 | 2012-03-22 | Universidad De Costa Rica | Conector estructural para bambú |
| FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN107108510B (zh) * | 2014-09-23 | 2020-10-23 | 活跃生物技术有限公司 | 用于治疗多发性骨髓瘤的喹啉甲酰胺 |
-
2015
- 2015-09-18 CN CN201580051397.XA patent/CN107108510B/zh active Active
- 2015-09-18 AU AU2015316824A patent/AU2015316824B2/en active Active
- 2015-09-18 PL PL15763622T patent/PL3041472T3/pl unknown
- 2015-09-18 EA EA201790687A patent/EA030948B1/ru not_active IP Right Cessation
- 2015-09-18 NZ NZ730816A patent/NZ730816A/en unknown
- 2015-09-18 US US15/510,728 patent/US9956212B2/en active Active
- 2015-09-18 ES ES15763622.6T patent/ES2631194T3/es active Active
- 2015-09-18 JP JP2017513751A patent/JP6647287B2/ja active Active
- 2015-09-18 MX MX2017003294A patent/MX366837B/es active IP Right Grant
- 2015-09-18 KR KR1020177010510A patent/KR102533033B1/ko active Active
- 2015-09-18 CA CA2961978A patent/CA2961978C/en active Active
- 2015-09-18 EP EP15763622.6A patent/EP3041472B1/en active Active
- 2015-09-18 WO PCT/EP2015/071391 patent/WO2016042112A1/en not_active Ceased
-
2017
- 2017-03-09 IL IL251043A patent/IL251043B/en active IP Right Grant
- 2017-04-04 ZA ZA2017/02377A patent/ZA201702377B/en unknown
-
2018
- 2018-04-06 US US15/947,279 patent/US10314836B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2631194T3 (es) | 2017-08-29 |
| US10314836B2 (en) | 2019-06-11 |
| US9956212B2 (en) | 2018-05-01 |
| ZA201702377B (en) | 2018-08-29 |
| JP2017528473A (ja) | 2017-09-28 |
| CA2961978A1 (en) | 2016-03-24 |
| EA030948B1 (ru) | 2018-10-31 |
| AU2015316824B2 (en) | 2020-10-29 |
| AU2015316824A1 (en) | 2017-04-27 |
| CA2961978C (en) | 2023-03-14 |
| CN107108510A (zh) | 2017-08-29 |
| MX366837B (es) | 2019-07-26 |
| KR102533033B1 (ko) | 2023-05-15 |
| CN107108510B (zh) | 2020-10-23 |
| EA201790687A1 (ru) | 2017-08-31 |
| WO2016042112A1 (en) | 2016-03-24 |
| BR112017004947A2 (pt) | 2017-12-05 |
| PL3041472T3 (pl) | 2017-08-31 |
| NZ730816A (en) | 2022-01-28 |
| KR20170052691A (ko) | 2017-05-12 |
| MX2017003294A (es) | 2017-06-23 |
| IL251043B (en) | 2020-02-27 |
| IL251043A0 (en) | 2017-04-30 |
| US20180228794A1 (en) | 2018-08-16 |
| US20170273967A1 (en) | 2017-09-28 |
| EP3041472B1 (en) | 2017-02-01 |
| EP3041472A1 (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6647287B2 (ja) | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド | |
| US12377054B2 (en) | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis | |
| JP6715833B2 (ja) | 白血病の治療に使用するためのキノリンカルボキサミド | |
| JP2017534652A5 (en:Method) | ||
| Jacobs et al. | PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies | |
| JP2017527627A (ja) | 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ | |
| HK1226643B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| HK1226643A1 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| US10154989B2 (en) | Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof | |
| BR112017004947B1 (pt) | Uso de um composto ou sal farmaceuticamente aceitável | |
| KR20230167019A (ko) | 이식편 대 숙주 질환의 치료를 위한 조성물 및 방법 | |
| JP2018513862A (ja) | シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 | |
| HK1237658B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| HK1237658A1 (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| George | Management of lupus nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190926 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6647287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |